PellizzariLPuppinCMariuzziL, et al.PAX8 expression in human bladder cancer.Oncol Rep.1 Nov. 2006;16(5):1015-1020. 10.3892/or.16.5.1015
2.
GaileyMPBellizziAM. Immunohistochemistry for the novel markers Glypican 3, pax8, and P40 (δnp63) in squamous cell and urothelial carcinoma.Am J Clin Pathol.1 Dec. 2013;140(6):872-880. 10.1309/ajcp4nskw5tlgtds
3.
TachaDZhouDChengL. Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol.July 2011;19(4):293-299. DOI: 10.1097/PAI.0b013e3182025f66
4.
CarvalhoJCThomasDGMcHughJB, et al.P63, CK7, pax8 and ini-1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high-grade tumours of the renal collecting system.Histopathology. 19 Jan. 2012;60(4):597-608. 10.1111/j.1365-2559.2011.04093.x
5.
LegesseTMatosoAEpsteinJI. PAX8 Positivity in nested variant of urothelial carcinoma: a potential diagnostic pitfall. Hum Pathol. 2019 Dec;94:11-15. doi: 10.1016/j.humpath.2019.09.012. Epub 2019 Oct 25. PMID: 31669177.
6.
TaylorASMcKenneyJKOsunkoyaAO, et al.PAX8 Expression and TERT promoter mutations in the nested variant of urothelial carcinoma: a clinicopathologic study with immunohistochemical and molecular correlates.Mod Pathol.June 2020;33(6):1165-1171. 10.1038/s41379-020-0453-z
7.
GorbokonNBaltruschatSLennartzM, et al.PAX8 Expression in cancerous and non-neoplastic tissue: a tissue microarray study on more than 17,000 tumors from 149 different tumor entities. Virchows Arch.6 Aug. 2024;485(3):491-507. 10.1007/s00428-024-03872-y
8.
OrdóñezNG. Value of PAX 8 immunostaining in tumor diagnosis: a review and update. Adv Anat Pathol. 2012 May;19(3):140-151. doi: 10.1097/PAP.0b013e318253465d. PMID: 22498579.
9.
TongG-XYuWMBeaubierNT, et al.Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study.Mod Pathol.Sept. 2009;22(9):1218-1227. 10.1038/modpathol.2009.88
10.
XiangHZhaoNChenZ. The detection of PAX8 in human upper urinary tract urothelial carcinoma. Int J Clin Exp Pathol. 2018 Nov 1;11(11):5394-5400. PMID: 31949621; PMCID: PMC6963013.
11.
ZhangXYaoJNiuN, et al.Sox17: a highly sensitive and specific Immunomarker for ovarian and endometrial carcinomas.Mod Pathol.Feb. 2023;36(2):100001. 10.1016/j.modpat.2022.100001.
